Continuation of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Clinical Centers (CPDPC-CCs) (U01 Clinical Trial Optional)
Funding Opportunity RFA-DK-19-009 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites U01 applications for the continuation of the consortium to study Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC) to conduct and complete ongoing studies on chronic pancreatitis (CP) and factors that increase the risk of pancreatic cancer in patients (children and adults) with CP, pancreatogenic (type 3c) diabetes (T3cDM) and in patients with newly diagnosed diabetes. The CPDPC is composed of several Clinical Centers (CC) and one Coordination and Data Management Center (CDMC) The...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 26, 2019 Category: Research Source Type: funding
Continuation of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Clinical Centers (CPDPC-CCs) (U01 Clinical Trial Optional)
This Funding Opportunity Announcement (FOA) invites U01 applications for the continuation of the consortium to study Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC) to conduct and complete ongoing studies on chronic pancreatitis (CP) and factors that increase the risk of pancreatic cancer in patients (children and adults) with CP, pancreatogenic (type 3c) diabetes (T3cDM) and in patients with newly diagnosed diabetes. The CPDPC is composed of several Clinical Centers (CC) and one Coordination and Data Management Center (CDMC) The Consortium since its establishment in Fall 2015 has conducted longitudinal clinic...
Source: NIDDK Funding Opportunities - September 26, 2019 Category: Endocrinology Source Type: funding
Limited Competition: Continuation of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Coordination and Data Management Center (CPDPC-CDMC) (U01 Clinical Trial Optional)
This Funding Opportunity Announcement (FOA) is a limited invitation for U01 application for one Coordination and Data Management Center (CDMC) to continue the consortium to study Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC) to conduct and complete ongoing studies on chronic pancreatitis (CP) and factors that increase the risk of pancreatic cancer in patients (children and adults) with CP, pancreatogenic (type 3c) diabetes (T3cDM) and in patients with newly diagnosed diabetes. The CPDPC is composed of several Clinical Centers (CC) and one Coordination and Data Management Center (CDMC) The Consortium since it...
Source: NIDDK Funding Opportunities - September 26, 2019 Category: Endocrinology Source Type: funding
Immunobiology of Xenotransplantation (U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-AI-19-042 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications from institutions to participate in the Immunobiology of Xenotransplantation Cooperative Research Program (IXCRP), for the development of preclinical porcine-to-nonhuman primate (NHP) models of pancreatic islet, kidney, heart, lung, or liver xenotransplantation. The goals of this program are to: (1) delineate the cellular and molecular mechanisms of xenograft rejection and/or the induction of immune tolerance; (2) develop effective strategies to improve xenograft survival; and (...
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 30, 2019 Category: Research Source Type: funding
Immunobiology of Xenotransplantation (U19 Clinical Trial Not Allowed)
Funding Opportunity RFA-AI-19-043 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications from institutions to participate in the Immunobiology of Xenotransplantation Cooperative Research Program (IXCRP), for the development of preclinical porcine-to-nonhuman primate (NHP) models of pancreatic islet, kidney, heart, lung, or liver xenotransplantation. The goals of this program are to: (1) delineate the cellular and molecular mechanisms of xenograft rejection and/or the induction of immune tolerance; (2) develop effective strategies to improve xenograft survival; and (...
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 30, 2019 Category: Research Source Type: funding
Advanced Clinical Trials to test Artificial Pancreas Device Systems in Type 1 Diabetes (U01 Clinical Trial Required)
Funding Opportunity RFA-DK-18-025 from the NIH Guide for Grants and Contracts. This FOA will support the conduct of advanced clinical trials designed to test the outpatient clinical safety and efficacy of artificial pancreas (AP) device systems in type 1 diabetes with the objective of improving glycemic control, reducing acute complications and improving quality of life. These trials should generate data able to satisfy safety and efficacy requirements by regulatory agencies regarding the clinical testing of AP device systems. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 28, 2019 Category: Research Source Type: funding
Data Coordinating Center for the Advanced Clinical Trials Consortium to Test Artificial Pancreas Device Systems (U24 Clinical Trial Not Allowed)
Funding Opportunity RFA-DK-18-026 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for a Data Coordinating Center (DCC) that will support the Advanced Clinical Trials to test Artificial Pancreas device systems. The applicant must have experience serving as the DCCfor studies on complex, clinical conditions including the testing of closed loop platforms for diabetes control.?The DCC will provide overall project coordination, administration, quality control, data management, and biostatistical support. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 28, 2019 Category: Research Source Type: funding
Advanced Clinical Trials to test Artificial Pancreas Device Systems in Type 1 Diabetes (U01 Clinical Trial Required)
This FOA will support the conduct of advanced clinical trials designed to test the outpatient clinical safety and efficacy of artificial pancreas (AP) device systems in type 1 diabetes with the objective of improving glycemic control, reducing acute complications and improving quality of life. These trials should generate data able to satisfy safety and efficacy requirements by regulatory agencies regarding the clinical testing of AP device systems.RFA-DK-18-025 (Source: NIDDK Funding Opportunities)
Source: NIDDK Funding Opportunities - January 28, 2019 Category: Endocrinology Source Type: funding
Data Coordinating Center for the Advanced Clinical Trials Consortium to Test Artificial Pancreas Device Systems (U24 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) invites applications for a Data Coordinating Center (DCC) that will support the Advanced Clinical Trials to test Artificial Pancreas device systems. The applicant must have experience serving as the DCCfor studies on complex, clinical conditions including the testing of closed loop platforms for diabetes control.?The DCC will provide overall project coordination, administration, quality control, data management, and biostatistical support.RFA-DK-18-026 (Source: NIDDK Funding Opportunities)
Source: NIDDK Funding Opportunities - January 28, 2019 Category: Endocrinology Source Type: funding
Mass Spectrometric Assays for the Reliable and Reproducible Detection of Proteins/Peptides of Importance in Obesity Research (U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-DK-19-001 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing the development of targeted mass spectrometric assays (e.g., Multiple Reaction Monitoring) for proteins and peptides of primary interest to the obesity research community (e.g., Adiponectin, Leptin, Resistin, Neuropeptide Y, Alpha-melanocyte-stimulating hormone, Peptide YY, Glucagon-like peptide 1, Ghrelin, Adrenocorticotropin, Corticotropin-releasing hormone, Gastrin, Cholecystokinin, Secretin, Vasoactive intestinal peptide, gastric-...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 23, 2019 Category: Research Source Type: funding
Mass Spectrometric Assays for the Reliable and Reproducible Detection of Proteins/Peptides of Importance in Obesity Research (U01 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing the development of targeted mass spectrometric assays (e.g., Multiple Reaction Monitoring) for proteins and peptides of primary interest to the obesity research community (e.g., Adiponectin, Leptin, Resistin, Neuropeptide Y, Alpha-melanocyte-stimulating hormone, Peptide YY, Glucagon-like peptide 1, Ghrelin, Adrenocorticotropin, Corticotropin-releasing hormone, Gastrin, Cholecystokinin, Secretin, Vasoactive intestinal peptide, gastric-inhibitory peptide, gastrin-releasing peptide, motilin, pancreatic polypeptide,RBP...
Source: NIDDK Funding Opportunities - January 23, 2019 Category: Endocrinology Source Type: funding
Human Islet Research Network - Consortium on Targeting and Regeneration (HIRN-CTAR) (U01 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) solicits applications for the Consortium on Targeting and Regeneration (CTAR) that supports the development of innovative strategies to increase or protect functional human beta cell mass in patients with Type-1 Diabetes (T1D) through the controlled manipulation of beta cell replication, islet cell plasticity, and the reprogramming of pancreatic non-beta cells into beta-like cells, or through shielding the residual beta cell mass from the autoimmune environment. CTAR is part of the Human Islet Research Network (HIRN). Olivier C Blondel, PHD | RFA-DK-18-014 (Source: NIDDK Funding Opportunities)
Source: NIDDK Funding Opportunities - November 2, 2018 Category: Endocrinology Source Type: funding
Human Islet Research Network - Consortium on Targeting and Regeneration (HIRN-CTAR) (U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-DK-18-014 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications for the Consortium on Targeting and Regeneration (CTAR) that supports the development of innovative strategies to increase or protect functional human beta cell mass in patients with Type-1 Diabetes (T1D) through the controlled manipulation of beta cell replication, islet cell plasticity, and the reprogramming of pancreatic non-beta cells into beta-like cells, or through shielding the residual beta cell mass from the autoimmune environment. CTAR is part of the Human Islet Resea...
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 31, 2018 Category: Research Source Type: funding
Human Pancreas Analysis Program for Type-2 Diabetes (HPAP-T2D) (U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-DK-18-016 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites cooperative agreement applications to expand the operational scope of the existing Human Pancreas Analysis Program (HPAP) to the study of pancreata recovered from tissue donors with Type 2 Diabetes (T2D) and related metabolic disorders. This FOA will support one team of investigators with combined expertise in human pancreas physiology and pathophysiology; collection, processing and multimodal analysis of human pancreatic tissues; and biological database building, curation and management, th...
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 10, 2018 Category: Research Source Type: funding
Human Pancreas Analysis Program (HPAP) (U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-DK-18-015 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites cooperative agreement applications to continue the mission of the existing Human Pancreas Analysis Program (HPAP). This FOA will support one team of investigators with combined expertise in human pancreas physiology and pathophysiology; collection, processing and multimodal analysis of human pancreatic tissues; and biological database building, curation and management, that will be tasked to: 1) identify, collect and intensively characterize primary pancreatic tissues from patients with type...
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 10, 2018 Category: Research Source Type: funding
